Grateful to have been part of CTAD 2022 conference in San Francisco and learn about steady advances made so far (Eisai and Alzheon in my opinion) in Alzheimer’s Disease Therapeutic Trials but also disappointing outcomes.

Unlike previous years, this one was full of tremendous hope for patients, their families and anyone that dedicated many years to advancing Alzheimer science with the goal of creating meaningful therapy to combat this challenging disease.

Was great to see many familiar faces that were part of our Bapanizumab journey at Elan years ago and meet new ones. La lotta continua.

Congrats to my colleagues at Alzheon, Inc. | Preserving Future Memories for the various presentations/discussions on ALZ801 (valiltramiprosate), which is currently the only oral anti-amyloid disease-modifying treatment in Phase 3.